Oncopeptides ingår partnerskap med SD Pharma för att ytterligare stärka Pepaxtis räckvidd i Spanien

Oncopeptides AB tillkännager idag ett partnerskap med SD Pharma, en ledande spansk läkemedelsdistributör specialiserad på onkologi och hematologi. Detta strategiska partnerskap kommer att bredda Pepaxtis räckvidd hos läkare över sjukhuskanaler i hela Spanien.

Under this collaboration, SD Pharma will enhance Oncopeptides’ commercial reach in regions and hospitals beyond its’ core focus areas. The partnership leverages the coordinated efforts of Medical Science Liaisons (MSLs), responsible for clinical education and medical support, and Regional Access Managers (RAMs), who manage treatment access and pharmacy logistics.

“SD Pharma’s established track record and extensive healthcare professional relationships position them as an excellent partner to further extend the reach of Pepaxti in Spain,” says Sofia Heigis, CEO of Oncopeptides. “This collaboration perfectly complements our existing national efforts and significantly advances our goal to serve an unmet medical need.”
Established in 2013, SD Pharma is recognized for its expertise in the commercialization of pharmaceuticals and medical devices. The company has successfully launched numerous products across oncology, hematology, and immunology and maintains strong partnerships with leading pharmaceutical companies such as BCG, Recordati, Laboratorios Leadiant, Chiesi and Airways Medical Devices.

“Partnering with Oncopeptides to commercialize Pepaxti significantly strengthens our portfolio and reinforces our commitment to serving hematology patients across Spain,” says Diego García, CEO at SD Pharma. “This partnership aligns perfectly with our commitment to supporting innovative and essential treatments, and we look forward to delivering significant value together in the fight against cancer.”

Activities by SD Pharma are expected to commence in Q3 2025, structured on a success-based model with no upfront or other costs for Oncopeptides.